Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.
Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.
Has no product on sale and funds its trials with money from investors; revenue so far has been small payments for research work done for others. Varegacestat, acquired from Ayala Pharmaceuticals, targets desmoid tumours, a rare soft-tissue growth with few treatments, so the main events are late-stage trial results and regulatory decisions.
Moat: none (IP / patents, data). Proprietary human antibody library aids target discovery but company is clinical-stage with no approved products.
Headquarters: Exton, Pennsylvania, US · Founded: 2005 · Employees: 177
Size Immunome (IMNM) is a United States Health Care company (Biotechnology) with a market value of $1.98B, the 1776th largest of 3,085 United States companies the cockpit tracks. Shares closed at $16.78 on 18 Nov 2026.
Performance Over six months the shares fell 22.1%, against -3.8% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 19 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median -4.4%).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $6.94M | $9.04M | $14.0M | $0 |
| Revenue growth | — | -23% | -36% | — | — |
| Gross profit | -$3.75M | $3.99M | $6.94M | $13.3M | -$631,000 |
| EBITDA | -$287M | -$211M | -$151M | -$109M | -$36.3M |
| Net income | -$283M | -$212M | -$293M | -$107M | -$36.9M |
| Free cash flow | -$239M | -$201M | -$118M | -$8.40M | -$28.9M |
| Capital expenditure | $9.67M | $9.69M | $7.17M | $831,000 | $248,000 |
| Total debt | $11.4M | $3.85M | $4.83M | $1.65M | $62,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunome IMNM | $1.98B | -22% | -100% | n/a | n/a | n/a |
| Sutro Biopharma STRO | n/a | -73% | n/a | n/a | n/a | n/a |
| Daiichi Sankyo 4568.T | $31.4B | +8% | +17% | 13% | 2.1× | 7.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMNM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.4% | -6.2% | 10th lowest of 20 |
| 6-month return | -22.1% | -3.8% | 5th lowest of 19 |
| Distance from 52-week high | -44.2% | -34.1% | 7th lowest of 21 |
| Revenue growth (TTM) | -100.0% | -4.4% | 2nd lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 5.0× | 3.5% | +41.4% |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | 10.2× | n/a | n/a |
| Sinocelltech 688520.SS | China | $1.90B | -35% | -40% | -75% | 13.6× | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | 53.6× | n/a | n/a |
| BioCryst Pharmaceuticals BCRX | United States | $1.88B | -16% | +60% | 42% | 2.4× | -11.0% | +117.9% |
| Replimune REPL | United States | $1.88B | +321% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $1.88B | +41% | +337% | -76% | 14.7× | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $1.87B | +175% | n/a | n/a | n/a | n/a | n/a |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $1.86B | -20% | -9% | 6% | 4.9× | 22.7% | +3.4% |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | 26.1× | n/a | n/a |
| Vera Therapeutics VERA | United States | $1.85B | -26% | n/a | -4,160% | 149.9× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 3.2× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| Hemab Therapeutics COAG | United States | $1.83B | +48% | n/a | n/a | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 0.4× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | 9,677.0× | n/a | n/a |
| Lycia Therapeutics LYCA | United States | $1.81B | n/a | -55% | -593% | n/a | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | 9.4× | n/a | n/a |
| Zenas BioPharma ZBIO | United States | $1.79B | +35% | -27% | -2,748% | 146.1× | n/a | n/a |